CTOs on the Move

Apple Discount Drugs

www.appledrugs.com

 
Apple Discount Drugs is a Salisbury, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Aeryon Labs Inc

Aeryon Labs Inc is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Top RX

If you think all generic pharmaceutical distributors are alike, it’s time to think again. We’re TOP RX, a leading national generic distributor that helps more than 5,000 pharmacies keep prices low on more than 2,800 generic pharmaceuticals. We call our company “TOP” for several reasons. We bring value to your business in many ways including our technological solutions, guaranteed product credibility and competitive pricing.

Halcyon Rehabilitation

Halcyon Rehabilitation enhances the quality of life in the community we service through top tier Physical Therapy, Occupational Therapy and Speech Language Pathology focused on long term care facilities. Our population focused programs allow us to assi...

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.

Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company`s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.